- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
VRIO Analysis of Sanofi-Aventis s Tender Offer for Genzyme
Posted by Zachary Edwards on Mar-22-2018
The VRIO Analysis of Sanofi-Aventis s Tender Offer for Genzyme will look at each of its internal resources one by one to assess whether these provide sustained competitive advantage. The Sanofi-Aventis s Tender Offer for Genzyme VRIO Analysis also mentions at each stage whether these resources could be improved to provide a greater competitive advantage. Lastly, the resources analysed are summarised as to whether they offer sustained competitive advantage, has an unused competitive advantage, temporary competitive advantage, competitive parity or competitive disadvantage.
Valuable
- The Sanofi-Aventis s Tender Offer for Genzyme VRIO Analysis shows that the financial resources of Sanofi-Aventis s Tender Offer for Genzyme are highly valuable as these help in investing into external opportunities that arise. These also help Sanofi-Aventis s Tender Offer for Genzyme in combating external threats.
- According to the VRIO Analysis of Sanofi-Aventis s Tender Offer for Genzyme, its local food products are a valuable resource as these are highly differentiated. This makes the perceived value for these by customers high. These are also valued more than the competition by customers due to the differentiation in these products.
- The Sanofi-Aventis s Tender Offer for Genzyme VRIO Analysis shows that Sanofi-Aventis s Tender Offer for Genzyme's employees are a valuable resource to the firm. A significant portion of the workforce is highly trained, and this leads to more productive output for the organisation. The employees are also loyal, and retention levels for the organisation are high. All of this translates into greater value for the end consumers of Sanofi-Aventis s Tender Offer for Genzyme's products.
- According to the VRIO Analysis of Sanofi-Aventis s Tender Offer for Genzyme, its patents are a valuable resource as these allow the firm to sell its products without competitive interference. This results in greater revenue for Sanofi-Aventis s Tender Offer for Genzyme. These patents also provide Sanofi-Aventis s Tender Offer for Genzyme with licensing revenue when it licenses these patents out to other manufacturers.
- The Sanofi-Aventis s Tender Offer for Genzyme VRIO Analysis shows that Sanofi-Aventis s Tender Offer for Genzyme’s distribution network is a valuable resource. This helps it in reaching out to more and more customers. This ensures greater revenues for Sanofi-Aventis s Tender Offer for Genzyme. It also ensures that promotion activities translate into sales as the products are easily available.
- According to the VRIO Analysis of Sanofi-Aventis s Tender Offer for Genzyme, its cost structure is not a valuable resource. This is because the methods of production lead to greater costs than that of competition, which affects the overall profits of the firm. Therefore, its cost structure is a competitive disadvantage that needs to be worked on.
- The Sanofi-Aventis s Tender Offer for Genzyme VRIO Analysis shows that the research and development at Sanofi-Aventis s Tender Offer for Genzyme is not a valuable resource. This is because research and development are costing more than the benefits it provides in the form of innovation. There have been very few innovative features and breakthrough products in the past few years. Therefore, research and development are a competitive disadvantage for Sanofi-Aventis s Tender Offer for Genzyme. It is recommended that the research and development teams are improved, and costs are cut for these.
Rare
- The financial resources of Sanofi-Aventis s Tender Offer for Genzyme are found to be rare according to the VRIO Analysis of Sanofi-Aventis s Tender Offer for Genzyme. Strong financial resources are only possessed by a few companies in the industry.
- The local food products are found to be not rare as identified by Sanofi-Aventis s Tender Offer for Genzyme VRIO Analysis. These are easily provided in the market by other competitors. This means that competitors can use these resources in the same way as Sanofi-Aventis s Tender Offer for Genzyme and inhibit competitive advantage. This means that the local food products result in competitive parity for Sanofi-Aventis s Tender Offer for Genzyme. As this resource is valuable, Sanofi-Aventis s Tender Offer for Genzyme can still make use of this resource.
- The employees of Sanofi-Aventis s Tender Offer for Genzyme are a rare resource as identified by the VRIO Analysis of Sanofi-Aventis s Tender Offer for Genzyme. These employees are highly trained and skilled, which is not the case with employees in other firms. The better compensation and work environment ensure that these employees do not leave for other firms.
- The patents of Sanofi-Aventis s Tender Offer for Genzyme are a rare resource as identified by the Sanofi-Aventis s Tender Offer for Genzyme VRIO Analysis. These patents are not easily available and are not possessed by competitors. This allows Sanofi-Aventis s Tender Offer for Genzyme to use them without interference from the competition.
- The distribution network of Sanofi-Aventis s Tender Offer for Genzyme is a rare resource as identified by the VRIO Analysis of Sanofi-Aventis s Tender Offer for Genzyme. This is because competitors would require a lot of investment and time to come up with a better distribution network than that of Sanofi-Aventis s Tender Offer for Genzyme. These are also possessed by very few firms in the industry.
Imitable
- The financial resources of Sanofi-Aventis s Tender Offer for Genzyme are costly to imitate as identified by the Sanofi-Aventis s Tender Offer for Genzyme VRIO Analysis. These resources have been acquired by the company through prolonged profits over the years. New entrants and competitors would require similar profits for a long period of time to accumulate these amounts of financial resources.
- The local food products are not that costly to imitate as identified by the VRIO Analysis of Sanofi-Aventis s Tender Offer for Genzyme. These can be acquired by competitors as well if they invest a significant amount in research and development. These also do not require years long experience. Therefore, the local food products by Sanofi-Aventis s Tender Offer for Genzyme provide it with a temporary competitive advantage that competitors can too acquire in the long run.
- The employees of Sanofi-Aventis s Tender Offer for Genzyme are also not costly to imitate as identified by the Sanofi-Aventis s Tender Offer for Genzyme VRIO Analysis. This is because other firms can also train their employees to improve their skills. These companies can also hire employees from Sanofi-Aventis s Tender Offer for Genzyme by offering better compensation packages, work environment, benefits, growth opportunities etc. This makes the employees of Sanofi-Aventis s Tender Offer for Genzyme a resource that provides a temporary competitive advantage. Competition can acquire these in the future.
- The patents of Sanofi-Aventis s Tender Offer for Genzyme are very difficult to imitate as identified by the VRIO Analysis of Sanofi-Aventis s Tender Offer for Genzyme. This is because it is not legally allowed to imitate a patented product. Similar resources to be developed and getting a patent for them is also a costly process.
- The distribution network of Sanofi-Aventis s Tender Offer for Genzyme is also very costly to imitate by competition as identified by the Sanofi-Aventis s Tender Offer for Genzyme VRIO Analysis. This has been developed over the years gradually by Sanofi-Aventis s Tender Offer for Genzyme. Competitors would have to invest a significant amount if they are to imitate a similar distribution system.
Organisation
- The financial resources of Sanofi-Aventis s Tender Offer for Genzyme are organised to capture value as identified by the VRIO Analysis of Sanofi-Aventis s Tender Offer for Genzyme. These resources are used strategically to invest in the right places; making use of opportunities and combatting threats. Therefore, these resources prove to be a source of sustained competitive advantage for Sanofi-Aventis s Tender Offer for Genzyme.
- The Patents of Sanofi-Aventis s Tender Offer for Genzyme are not well organised as identified by the Sanofi-Aventis s Tender Offer for Genzyme VRIO Analysis. This means that the organisation is not using these patents to their full potential. An unused competitive advantage exists that can be changed into a sustainable competitive advantage if Sanofi-Aventis s Tender Offer for Genzyme starts selling patented products before the patents expire.
- The distribution network of Sanofi-Aventis s Tender Offer for Genzyme is organised as identified by the VRIO Analysis of Sanofi-Aventis s Tender Offer for Genzyme. Sanofi-Aventis s Tender Offer for Genzyme uses this network to reach out to its customers by ensuring that products are available on all of its outlets. Therefore, these resources prove to be a source of sustained competitive advantage for Sanofi-Aventis s Tender Offer for Genzyme.
From the VRIO Analysis of Sanofi-Aventis s Tender Offer for Genzyme, it was identified that the financial resources and distribution network provide a sustained competitive advantage. The patents are a source of unused competitive advantage. There exists a temporary competitive advantage for employees. There exists a competitive parity for local food products. Lastly, the cost structure of Sanofi-Aventis s Tender Offer for Genzyme is a competitive disadvantage. Research and Development is also a competitive disadvantage.
Warning! This article is only an example and cannot be used for research or reference purposes. If you need help with something similar, please submit your details here.
Quintin Geoffrey
5.0
BTW which type of words should I choose for the writer because you are so generous who revised my assignment and provided me correct assignment within six hours.
Peter Na
5.0
No need to be concerned about plagiarism and proofreading since this service has been providing you with the report on your main concerns.
Fai Ning
4.0
The dissertation was OKAY in all respects. Somehow I was confused with two references and thought that I should erase them from the paper. However, the supervisor accepted every point and didn't underline an error in the paper.
Ekavir Harish
5.0
The writer also shared many helpful tips to enhance the writing style. I'll try my best to act upon his advice and make my writing style just like him.
Next Articles
- Standard International, Inc. (A) Vrio Analysis
- Merck: Managing Vioxx (G) Vrio Analysis
- Merck: Managing Vioxx (E), Portuguese Version Vrio Analysis
- Elan Corporation Turnaround Vrio Analysis
- ESurg (B): Second Round Financing Vrio Analysis
- HR 3509 Vrio Analysis
- Vick International Division: Tom McGuire Vrio Analysis
- AtHomeCare, Inc.: Health Care Services Rollup Vrio Analysis
- Ligand Pharmaceuticals Incorporated Vrio Analysis
- Merck/Schering Plough Merger (A) Vrio Analysis
Previous Articles
- Genzyme: The Synvisc One Investment Decision Vrio Analysis
- Medfield Pharmaceuticals Vrio Analysis
- Merck: Managing Vioxx (D) Vrio Analysis
- Procurement At Betapharm Corp. (A), Chinese Version Vrio Analysis
- Healthcare Brands Corp. Vrio Analysis
- Roche Holding AG: Funding The Genentech Acquisition Vrio Analysis
- ESurg (A): Negotiating The Start Up Vrio Analysis
- Merck: Managing Vioxx (A), Portuguese Version Vrio Analysis
- Disclosure Dilemma: Financial Reporting Of Contingent And Environmental Liabilities Vrio Analysis
- Merck: Managing Vioxx (F), Portuguese Version Vrio Analysis
Be a great writer or hire a greater one!
Academic writing has no room for errors and mistakes. If you have BIG dreams to score BIG, think out of the box and hire Case48 with BIG enough reputation.
Our Guarantees
Interesting Fact
Most recent surveys suggest that around 76 % students try professional academic writing services at least once in their lifetime!